Streetbeat News

CMND

Clearmind Medicine Inc.

https://www.clearmindmedicine.com

Industry

Biotechnology

Clearmind Medicine Inc., a pre-clinical pharmaceutical company, develops novel psychedelic medicines to treat under-served health problems. It develops treatments for alcohol use disorders, including binge drinking and eating disorders, as well as depression, binge eating, psychotherapy, mental health issues, and other binge behaviors. The company was formerly known as Cyntar Ventures Inc. and changed its name to Clearmind Medicine Inc. in March 2021. Clearmind Medicine Inc. was incorporated in 2017 and is based in Vancouver, Canada.

Open

1.40

Mkt cap

5.7M

Volume

41K

High

1.40

P/E Ratio

-1.14

52-wk high

6.80

Low

1.36

Div yield

N/A

52-wk low

0.92

Clearmind Medicine has received FDA clearance for its IND application of the MEAI-based CMND-100 oral capsule. This allows the company to proceed with a Phase I/IIa clinical trial for alcohol use disorder in the US. The trial has already been approved in Israel.

Portfolio Pulse from Benzinga Newsdesk

July 16, 2024 | 1:03 pm

Clearmind Medicine has been granted patent approval in Hong Kong for its treatment of binge behaviors.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 8:07 pm

Clearmind Medicine Inc. (NASDAQ:CMND) shares surged after the company announced a patent approval in Hong Kong for its MEAI-based binge behavior regulator program. The stock saw heavy trading volume, significantly above its 100-day average.

Portfolio Pulse from Erica Kollmann

June 28, 2024 | 5:11 pm

Clearmind Medicine shares are trading higher following the announcement of a patent approval in Hong Kong for its MEAI-based binge behavior regulator program.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 3:32 pm

Clearmind Medicine has been granted patent approval in Hong Kong for its treatment of binge behaviors, expanding its intellectual property protection in the psychedelic space.

Portfolio Pulse from Benzinga Newsdesk

June 28, 2024 | 12:00 pm

Clearmind Medicine shares are trading higher following the announcement of an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:59 am

Clearmind Medicine has signed an exclusive patent licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. The agreement grants Clearmind exclusive rights to develop, manufacture, and commercialize compounds for treating PTSD and other mental health disorders.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:58 am

Clearmind Medicine Inc (NASDAQ:CMND) announced advancements in its MEAI-based alcohol substitute beverage program, including the initiation of the last pre-clinical study and the granting of patents in the U.S., India, and Europe. The no/low alcohol category is expected to grow at a CAGR of more than 6% between 2023 and 2027.

Portfolio Pulse from Adam Eckert

June 11, 2024 | 4:39 pm

Market-Moving News for June 11th includes significant developments for Molecular Partners, QuantaSing Group Limited, and Clearmind Medicine. Molecular Partners announced the debut of their lead Raido-DARPin therapy candidate MP0712, QuantaSing Group Limited announced a share repurchase program, and Clearmind Medicine advanced its MEAI-based alcohol substitute beverage program.

Portfolio Pulse from ryanfaloona@benzinga.com

June 11, 2024 | 12:29 pm

Clearmind Medicine shares are trading higher following the company's announcement of progress in its proprietary MEAI-based alcohol substitute beverage program.

Portfolio Pulse from Benzinga Newsdesk

June 11, 2024 | 12:09 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.